Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration

Bill title was amended to specify scheduling of 'an organic psilocybin substance or crystalline polymorph psilocybin approved by the Food and Drug Administration and the Drug Enforcement Administration'

Header information changed from 'Committee Substitute' to 'HB3343 H HHR AMT' with adoption/rejection status added

Removed Committee Substitute header text and page numbering artifacts from the final adopted version

Added extensive lists of synthetic cannabinoids (JWH series, CP series, etc.), synthetic cathinones (bath salts), and other research chemicals to Schedule I.

Added a specific provision allowing FDA-approved crystalline polymorph psilocybin (COMP360) to be prescribed and distributed if approved by both the FDA and DEA.

Replaced the original drug list with a new, much longer list containing hundreds of substances including detailed chemical structures and trade names.

Added catch-all language for synthetic chemical compounds that are cannabinoid receptor type 1 agonists not listed in other schedules.

Added specific provision allowing prescription, distribution, and marketing of crystalline polymorph psilocybin (COMP360) if approved by the FDA and scheduled by the DEA.

Expanded Schedule I to include numerous synthetic cannabinoids (JWH series, CP series, etc.), synthetic opioids (fentanyl analogs, nitazenes), and novel psychoactive substances not previously listed.

Added comprehensive lists of synthetic cathinones, benzodiazepines, and other controlled substances including specific chemical names and trade names.

Included temporary emergency scheduling provision for specific fentanyl analogs and related substances.

Updated hallucinogenic substances list to include additional tryptamines and synthetic compounds not previously enumerated.